Key Stats for Veeva Systems Stock
- Current Price: ~$179 (June 3, 2026)
- Q1 FY2027 Total Revenue: $883M, +16% YoY
- Q1 FY2027 Adjusted EPS: $2.24, +14% YoY
- Q1 FY2027 Non-GAAP EBIT: $395M, +13% YoY
- Q1 FY2027 Free Cash Flow: $1.1B, +29% YoY
- TIKR Model Price Target (January 2031): $337
- Implied Upside: ~89%
Veeva Systems Stock Beats Q1 FY2027 Estimates as Falcon AI Platform Takes Shape
Veeva Systems (VEEV) delivered a strong Q1 FY2027, reporting total revenue of $883M and adjusted EPS of $2.24, both ahead of Street expectations, as the life sciences cloud vendor simultaneously launched what management described as its most disruptive product since the original Vault platform.
Revenue of $883M came in roughly 3% above the consensus estimate of $858M, extending Veeva’s track record of consistent beats into what is shaping up as a pivotal product cycle year.
Adjusted EPS of $2.24 topped the $2.14 Street estimate by nearly 5%, with non-GAAP EBIT reaching $395M against a $382M consensus, underscoring that the beat was operational and not driven by below-the-line items.
Peter Gassner, Chief Executive Officer, stated on the Q1 FY2027 earnings call that “there’s a lot of things to unpack” in Falcon, framing the agentic labor platform as “the next chapter of Veeva in our industry cloud,” representing a category of revenue the company has never addressed before.
Veeva Falcon is the strategic development that gives this quarter its longer-term significance: rather than an incremental AI feature layer, Falcon is designed to replace high-volume repetitive jobs in life sciences workflows, specifically the intake and classification of clinical trial documentation and the triage and categorization of safety cases, initially priced on a per-document and per-case basis.
The professional services line added a noteworthy data point: Brian Van Wagener, Chief Financial Officer, confirmed on the Q1 FY2027 earnings call that Q1 was “a record quarter for our services team,” driven by strong R&D project execution and business consulting activity, with Vault CRM migration work contributing but not leading the outperformance.
On the commercial side, Vault CRM continued to gain ground in the migration of large pharma customers away from the Salesforce-based legacy platform, with Paul Shawah, EVP Strategy, reporting an overall win rate above 80%, more than 150 customers live on Vault CRM, and two significant recent additions in Teva and Merck KGaA, bringing the total top-20 wins to 10 against 6 for Salesforce, with 4 decisions still outstanding.
The Ostro acquisition, closed late in Q1, added a brand engagement platform connecting biopharma companies with healthcare professionals and patients via compliant AI-powered interfaces, with Van Wagener guiding for approximately $10M in contribution over the remaining three quarters of FY2027.
Is Veeva Systems Stock Undervalued? TIKR Valuation Model Results
TIKR’s base case values Veeva Systems at approximately $337 by January 2031, implying around 89% total return from the current price of roughly $179, or about 15% annualized over the next 4.7 years.
If Veeva sustains a revenue CAGR of around 13% and expands net income margins toward 40%, consistent with the mid-case trajectory, the model produces a stock price of approximately $337 and an IRR of around 14%.
Should revenue growth run closer to the 11% low-case scenario, reflecting a slower adoption curve for Falcon and softer Crossix trends, the model prices Veeva Systems stock at approximately $414 by January 2031, with an annualized return of roughly 10%.
In the high-case scenario, where revenue CAGR reaches approximately 14% and net income margins approach 43%, TIKR’s model points to a stock price of around $740 by January 2035, representing an IRR of approximately 18%.
How did Veeva Systems perform in Q1 FY2027 earnings?
Veeva Systems delivered adjusted EPS of $2.24 in Q1 FY2027, beating the $2.14 Street estimate by roughly 5%.
Revenue reached $883M, up 16% year-over-year, with non-GAAP EBIT of $395M beating consensus by approximately 3.6%.
Record professional services output, Crossix strength, and Vault CRM migration momentum drove the outperformance.
Management raised commercial subscription guidance for the full year, citing the Ostro acquisition contributing approximately $10M over the remaining three quarters.
Is Veeva Systems stock undervalued?
TIKR’s base case values Veeva Systems stock at approximately $337 by January 2031, implying around 89% total return from the current price of $179, or roughly 15% annualized.
Free cash flow surged 29% year-over-year to $1.1B in Q1 FY2027, supporting the cash generation thesis behind the $2B share repurchase program.
The key variable is Falcon adoption: if early adopter deployments in clinical documentation processing convert to broad enterprise uptake, the mid-case trajectory is well supported.
Should You Invest in Veeva Systems Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Veeva Systems stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Veeva Systems Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze VEEV stock on TIKR for Free →
#Adessonews seleziona nella rete articoli di particolare interesse.
Se vuoi leggere l’articolo completo clicca sul seguente link
Gian Estrada
Source link
